Showing 2391-2400 of 2532 results for "".
- Outrun the Sun Marks 10 Years of Sun Safety Education and Melanoma Researchhttps://practicaldermatology.com/news/20140428-outrun_the_sun_marks_10_years_of_sun_safety_education_and_melanoma_research/2459253/Outrun the Sun, Inc. (OTS), a nonprofit organization that has raised more than $1 million in support of skin cancer education and melanoma research, celebrates their 10 year anniversary. OTS was formed by Anita Day, Jonna MacDougall, Marci Reddick and Jennifer Patton Sarno because they h
- XOMA Finalizes Gevokizmab Phase III Clinical Program in Pyoderma Gangrenosumhttps://practicaldermatology.com/news/20140428-xoma_finalizes_gevokizmab_phase_3_clinical_program_in_pyoderma__gangrenosum/2459254/Xoma Corporation finalized the plans for gevokizumab Phase III Program in Pyoderma Gangrenosum (PG). The Phase III Study will include two double-blind placebo-controlled clinical studies with 60 patients who have active PG. Paul Rubin, Senior Vice President,
- Nuvo Research Announces Collaboration to Develop Topical Dermatology Productshttps://practicaldermatology.com/news/20140423-nuvo_research_announces_collaboration_to_develop_topical_dermatology_products/2459258/Nuvo Research Inc. is collaborating with Ferndale Laboratories, Inc. and a leading Contract Research Organization (CRO) with significant dermatology experience to develop two topical dermatology products based on Nuvo's patented Multiplexe
- Phase 3 Results Promising for Oral Psoriasis Agenthttps://practicaldermatology.com/news/20140422-phase_3_results_promising_for_oral_psoriasis_agent/2459260/Results from two pivotal Phase 3 trials from the Oral treatment Psoriasis Trials (OPT) Program indicate that the investigational oral Janus kinase (JAK) inhibitor tofacitinib (Pfizer) is both safe and effective for patients with moderate to severe psoriasis. The OPT Pivotal #1 and OPT Pivotal #2 stu
- La Roche-Posay's "Dermatologist from the Heart" Accepting Applicationshttps://practicaldermatology.com/news/20140421-la_roche-posays_dermatologist_from_the_heart_accepting_applications/2459264/La Roche-Posay is accepting grant application for its “Dermatologist from the Heart” program in the United States. Now in its second year in the US, “Dermatologist from the Heart” aims to support initiatives designed to enhance the quality of life for patients. Through this program, the La Fon
- Mirvaso Now Available in the UKhttps://practicaldermatology.com/news/20140417-mirvaso_now_available_in_the_uk/2459269/Mirvaso (brimonidine) 3mg/g gel, an alpha-2 adrenergic agonist indicated for the symptomatic treatment facial erythema associated with rosacea in adult patients, is now available in the UK. The active ingredient, brimonidine, restricts excessive blood f
- April is Rosacea Awareness Monthhttps://practicaldermatology.com/news/20140401-april_is_rosacea_awareness_month/2459281/April is Rosacea Awareness Month and the National Rosacea Society encourages physicians and patients to raise awareness of the disease and its impact on affected individuals. This red-face disorder affects more than 16 million Americans between the ages of 30 and 60. It covers the spectru
- Anti-Interleukin-23 Monoclonal Antibody Guselkumab: Significant Efficacy In Moderate To Severe Plaque Psoriasishttps://practicaldermatology.com/news/20140324-anti-interleukin-23_monoclonal_antibody_guselkumab_significant_efficacy_in_moderate_to_severe_plaque_psoriasis/2459298/New findings presented for the first time at the 2014 Annual Meeting of the American Academy of Dermatology (AAD) showed up to 86 percent of patients with moderate to severe plaque psoriasis receiving guselkumab (CNTO 1959) achieved a Physician's Global Assessment (PGA) score of cleared or minimal a
- ADAM Names June McKernan “Practice Manager Of The Year”https://practicaldermatology.com/news/20140323-adam_names_june_mckernan_practice_manager_of_the_year/2459299/The Association of Dermatology Administrators and Managers (ADAM) named June McKernan, Administrator, of Patient Preferred Dermatology of Los Alamitos, CA, the recipient of the organization's inaugural Practice Manager of the Year award. She w
- FDA Approves Novartis Drug Xolair for Chronic Idiopathic Urticariahttps://practicaldermatology.com/news/20140321-fda_approves_novartis_drug_xolair_for_chronic_idiopathic_urticaria/2459302/The FDA approved Xolair (Novartis, omalizumab) for the treatment of chronic idiopathic urticaria (CIU) for patients 12 years of age and older who remain symptomatic despite treatment with H1-antihistamine therapy. Xolair is not used to treat other forms of urticaria (